Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism

Therapeutic Apheresis and Dialysis

Volumn 10, Issue 3, 2006, Pages 262-266

  Kazama, Junichiro James ^a   Omori, Kentaro ^a   Yamamoto, Suguru ^a   Ito, Yumi ^a   Maruyama, Hiroki ^a   Narita, Ichiei ^a   Gejyo, Fumitake ^a   Iwasaki, Yoshiko ^b   Fukagawa, Masafumi ^c  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Oita University of Nursing and Health Sciences   (Japan)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone Histomorphometry; Hemodialysis; Mild Secondary Hyperparathyroidism; Osteoprotegerin

Indexed keywords

GLYCOPROTEIN; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE BIOPSY; BONE METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ILIAC BONE; MALE; MORPHOMETRICS; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SECONDARY HYPERPARATHYROIDISM; UREMIA;

ADULT; AGED; BIOPSY; BONE AND BONES; BONE RESORPTION; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RENAL DIALYSIS;

EID: 33745536738     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2006.00375.x     Document Type: Article

References (15)

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
2. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases JAMA 2004;292:490-5.
3. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-57.
4. Udagawa N, Takahashi N, Yasuda H et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000;141:3478-84.
5. Yamamoto M, Murakami T, Nishikawa M et al. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. Endocrinology 1998;139:4012-15.
6. Coen G, Ballanti P, Balducci A et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002;17:233-8.
7. Haas M, Leko-Mohr Z, Roschger P et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 2002;39:580-6.
8. Kazama JJ, Shigematsu T, Yano K et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002;39:525-32.
9. Avbersek-Luznik I, Malesic I, Rus I, Marc J. Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 2002;40:1019-23.
10. Kazama JJ, Kato H, Sato T et al. Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 2002;17:1860-1.
11. Yano K, Tsuda E, Washida N et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999;14:518-27.
12. Kazama JJ, Gejyo F, Ejiri S et al. Application of confocal laser scanning microscopy to the observation of bone biopsy specimens. Bone 1993;14:885-9.
13. Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry nomenclature, symbols and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;5:595-610.
14. Kazama JJ. Osteoprotegerin and bone mineral metabolism in renal failure. Curr Opin Nephrol Hypertens 2004;13:411-15.
15. Coen G, Mantella D, Manni M et al. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 2005;68:1840-8.